Quick Answer
Pacira BioSciences, Inc. reported Net Income Loss of $7.03 million for the year ending 2025.
- Pacira BioSciences, Inc. showed an increase of +107.1% in Net Income Loss from 2024 to 2025.
- This data is from Pacira BioSciences, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2014: -$11.48 million | Q2 2014: -$5.04 million | Q3 2014: -$3.00 million | Q4 2014: -$13.72 million | Q1 2015: $1.26 million | Q2 2015: $8.0 thousand | Q3 2015: $3.09 million | Q4 2015: -$2.50 million | Q1 2016: -$3.85 million | Q2 2016: -$7.96 million | Q3 2016: -$22.16 million | Q4 2016: -$3.97 million | Q1 2017: -$19.87 million | Q2 2017: -$19.74 million | Q3 2017: -$7.60 million | Q4 2017: $4.60 million | Q1 2018: -$10.68 million | Q2 2018: $2.56 million | Q3 2018: -$640.0 thousand | Q4 2018: $8.29 million | Q1 2019: -$2.77 million | Q2 2019: $2.73 million | Q3 2019: -$6.09 million | Q4 2019: -$4.89 million | Q1 2020: $8.16 million | Q2 2020: -$7.27 million | Q3 2020: $130.12 million | Q4 2020: $14.51 million | Q1 2021: $10.37 million | Q2 2021: $19.08 million | Q3 2021: $17.66 million | Q1 2022: $6.83 million | Q2 2022: $19.88 million | Q3 2022: -$693.0 thousand | Q1 2023: -$19.54 million | Q2 2023: $25.76 million | Q3 2023: $10.86 million | Q1 2024: $8.98 million | Q2 2024: $18.89 million | Q3 2024: -$143.47 million | Q1 2025: $4.81 million | Q2 2025: -$4.85 million | Q3 2025: $5.43 million.
- Over the full 17 years of available data (2009 to 2025), Pacira BioSciences, Inc.'s Net Income Loss has grown by 122.2%.
- Historical annual values: Fiscal year 2025: $7.03 million | Fiscal year 2024: -$99.56 million | Fiscal year 2023: $41.96 million | Fiscal year 2022: $15.91 million | Fiscal year 2021: $41.98 million | Fiscal year 2020: $145.52 million | Fiscal year 2019: -$11.02 million | Fiscal year 2018: -$471.0 thousand | Fiscal year 2017: -$42.61 million | Fiscal year 2016: -$37.95 million | Fiscal year 2015: $1.86 million | Fiscal year 2014: -$13.72 million | Fiscal year 2013: -$63.91 million | Fiscal year 2012: -$52.28 million | Fiscal year 2011: -$43.33 million | Fiscal year 2010: -$27.15 million | Fiscal year 2009: -$31.71 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: